Assessing biotherapeutic developability using advanced mass spectrometry workflows

This case study explores how Sanofi uses mass spectrometry (MS) workflows to assess the developability of novel biotherapeutics, focusing on identifying chemical liabilities and key attributes that influence stability, efficacy, and manufacturability. The study highlights the increasing complexity of modern biotherapeutics and the need for high-throughput, data-driven analytical approaches.

Using the Genedata Expressionist platform, Sanofi implemented configurable, automated MS data processing workflows to integrate and analyze complex datasets from multiple instruments and assays. The approach enables improved data transparency, standardization, and scalability, supporting rapid identification of modifications and structural features that may impact product quality. This enhanced analytical capability allows earlier decision-making, reduces development risk, and accelerates the optimization of next-generation therapeutic candidates.

Resource details:

• Resource type: Case study
• Page count: 4
• Read time: 6 mins